SLC36A2: A Potential Drug Target and Biomarker for Proton/Amino Acid Transporter 2

Target Name: SLC36A2

NCBI ID: G153201

SLC36A2

SLC36A2: A Potential Drug Target and Biomarker for Proton/Amino Acid Transporter 2

Proton/amino acid transporter 2 (SLC36A2) is a protein that plays a crucial role in the regulation of amino acid transport in the body. It is a member of the selective transportion system (SLC) family, which includes several proteins involved in the transport of different types of molecules across cell membranes. SLC36A2 is expressed in many different tissues and is involved in the transport of both proton and amino acids, which are essential nutrients for the growth, development, and survival of all living organisms.

SLC36A2 has been identified as a potential drug target due to its involvement in various physiological processes that are important for human health. For example, alterations in SLC36A2 expression levels have been associated with a range of diseases, including cancer, neurodegenerative diseases, and gastrointestinal disorders. In addition, SLC36A2 has been shown to play a key role in the regulation of cellular signaling processes that are involved in various cellular processes, including cell growth, apoptosis, and inflammation.

Despite the potential clinical applications of SLC36A2 as a drug target, much of the research on this protein has focused on its role in disease progression and pathophysiology. little is known about its potential as a biomarker, although some studies have suggested that SLC36A2 may be involved in the diagnosis and prognosis of certain diseases.

Here we will explore the biology and function of SLC36A2, with a focus on its potential as a drug target and biomarker. We will discuss the evidence for its involvement in disease processes, including its association with cancer, neurodegenerative diseases, and gastrointestinal disorders. We will also examine the potential clinical applications of SLC36A2 as a drug target and biomarker, including its potential as a diagnostic tool and target for small molecule inhibitors.

Biomarker Potential

SLC36A2 has been shown to play a role in the regulation of cellular signaling processes that are involved in various cellular processes, including cell growth, apoptosis, and inflammation. One of the most well-studied functions of SLC36A2 is its role in the regulation of cell apoptosis. SLC36A2 has been shown to play a key role in the regulation of cell death by promoting the production of pro-apoptotic factors and inhibiting the production of anti-apoptotic factors.

In addition, SLC36A2 has been shown to play a role in the regulation of cell proliferation. SLC36A2 has been shown to promote the production of S-phase myeloid leukemia (MCL) cells and to inhibit the production of G1-phase myeloid leukemia (ML) cells. These findings suggest that SLC36A2 may be involved in the regulation of cell proliferation and that alterations in its expression levels may have implications for the development and treatment of cancer.

Disease Association

SLC36A2 has been associated with a number of diseases, including cancer, neurodegenerative diseases, and gastrointestinal disorders. One of the most well-studied associations of SLC36A2 with cancer is its involvement in the regulation of cell apoptosis. Several studies have shown that SLC36A2 is involved in the regulation of cell death by promoting the production of pro-apoptotic factors and inhibiting the production of anti-apoptotic factors. These findings suggest that SLC36A2 may be involved in the regulation of

Protein Name: Solute Carrier Family 36 Member 2

Functions: Electrogenic proton/amino acid symporter with a high selectivity for the small side chains amino acids glycine, alanine and proline, where both L- and D-enantiomers are transported. Extension of the backbone length, as in beta-alanine and 4-aminobutanoate or methylation of the amino group, as in sarcosine and N,N-dimethylglycine, are also tolerated but decrease transport efficiency. A free carboxyl group is preferred

The "SLC36A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC36A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets